Canopy Growth (CGC) Non-Current Assets (2017 - 2026)
Canopy Growth (CGC) reported Non-Current Assets of $429.7 million for Q1 2026, down 1.05% on a YoY basis from $434.3 million in Q1 2025, and down 38.53% sequentially from $699.0 million in Q4 2025.
Canopy Growth (CGC) Non-Current Assets (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Non-Current Assets data on file, last reported at $429.7 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 1.05% year-over-year to $429.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 billion (down 18.0% YoY), and the FY2026 full-year result was $429.7 million, down 1.05% from the prior year.
- Non-Current Assets declined to $429.7 million in Q1 2026, from $699.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $3.1 billion in Q1 2022 to a low of $429.7 million in Q1 2026.
- A 5-year average of $941.3 million and a median of $707.0 million in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets slumped 67.08% in 2023 and gained 3.16% in 2024, its largest moves.
- Tracing CGC's Non-Current Assets over 5 years: stood at $1.3 billion in 2022, then tumbled by 46.38% to $707.0 million in 2023, then climbed by 3.16% to $729.3 million in 2024, then decreased by 4.16% to $699.0 million in 2025, then tumbled by 38.53% to $429.7 million in 2026.
- Business Quant data shows CGC's Non-Current Assets at $429.7 million in Q1 2026, $699.0 million in Q4 2025, and $453.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | 429.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 429.70 Mn |
| Dec 31, 2025 | 699.03 Mn |
| Sep 30, 2025 | 453.44 Mn |
| Jun 30, 2025 | 433.97 Mn |
| Mar 31, 2025 | 434.27 Mn |
| Dec 31, 2024 | 729.34 Mn |
| Sep 30, 2024 | 616.27 Mn |
| Jun 30, 2024 | 678.82 Mn |
| Mar 31, 2024 | 689.53 Mn |
| Dec 31, 2023 | 706.97 Mn |
| Sep 30, 2023 | 876.12 Mn |
| Jun 30, 2023 | 973.23 Mn |
| Mar 31, 2023 | 1.01 Bn |
| Dec 31, 2022 | 1.32 Bn |
| Sep 30, 2022 | 1.39 Bn |
| Jun 30, 2022 | 1.51 Bn |
| Mar 31, 2022 | 3.06 Bn |
| Dec 31, 2021 | 3.43 Bn |
| Sep 30, 2021 | 3.17 Bn |
| Jun 30, 2021 | 3.49 Bn |